TITLE: Altered Astrocyte-Neuron Interactions and Epileptogenesis in Tuberous Sclerosis Complex Disorder

Similar documents
TITLE: Altered Astrocyte-Neuron Interactions and Epileptogenesis in Tuberous Sclerosis Complex Disorder

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

CONTRACTING ORGANIZATION: Rutgers, the State University of New Jersey New Brunswick, NJ 08901

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Fort Detrick, Maryland

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

Award Number: W81XWH TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis

TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

La Jolla, CA Approved for Public Release; Distribution Unlimited

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center Nashville, TN

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

CONTRACTING ORGANIZATION: Cleveland Clinic Foundation Cleveland, OH 44195

Detection of Prostate Cancer Progression by Serum DNA Integrity

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

TITLE: Astrocytic Disruption in Traumatic Brain Injury and Alzheimer s Disease. CONTRACTING ORGANIZATION: Northwestern University, Chicago, IL 60611

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

TITLE: Treatment of Dengue Virus Infection with Repurposed Pharmaceuticals that Inhibit Autophagy

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

Approved for public release; distribution unlimited

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Investigating the Role of TBX2 in the Inhibition of Senescence in Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

TITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

Award Number: W81XWH

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland X Approved for public release; distribution unlimited

TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets

TITLE: The Importance of Autophagy in Breast Cancer Development and Treatment

TITLE: Maximizing Energy After Traumatic Brain Injury: A Novel Intervention

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Central Tolerance Blockade to Augment Checkpoint Immunotherapy in Melanoma

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

The Role of Brain Inflammation in Epileptogenesis in TSC. CONTRACTING ORGANIZATION: Washington University School of Medicine St Louis, M

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

TITLE: Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cells

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans

TITLE: Functional Genetics for Predisposition to Development of Type 2 Diabetes in Obese Individuals. PRINCIPAL INVESTIGATOR: Assia Shisheva

TITLE: Post-Traumatic Headache and Psychological Health: Mindfulness Training for Mild Traumatic Brain Injury

Award Number: W81XWH TITLE: "Longitudinal Study of a Novel Performance-based Measure of Daily Function."

TITLE: Responsiveness of a Neuromuscular Recovery Scale for Spinal Cord Injury: Inpatient and Outpatient Rehabilitation

CONTRACTING ORGANIZATION: Spaulding Rehabilitation Hospital, Boston, MA 02129

Expression and Promoter Methylation of P16INK4A During Estrogen-Induced Mammary Carcinogenesis in the ACI Rat. Omaha, NE

TITLE: Development of a Blood-Based Biomarker Panel for Indeterminate Lung Nodules

TITLE: TREATMENT OF ENDOCRINE-RESISTANT BREAST CANCER WITH A SMALL MOLECULE C-MYC INHIBITOR

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc)

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

TITLE: Homeostatic and Circadian Abnormalities in Sleep and Arousal in Gulf War Syndrome

Transcription:

AWARD NUMBER: W81XWH-12-1-0196 TITLE: Altered Astrocyte-Neuron Interactions and Epileptogenesis in Tuberous Sclerosis Complex Disorder PRINCIPAL INVESTIGATOR: Dr. David Sulzer, Ph.D. CONTRACTING ORGANIZATION: Columbia University, New York, NY 10032 REPORT DATE: August 2016 TYPE OF REPORT: Final PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE August 2016 4. TITLE AND SUBTITLE 2. REPORT TYPE Final report Altered Astrocyte-Neuron Interactions and Epileptogenesis in Tuberous Sclerosis Complex Disorder 3. DATES COVERED 1 JUNE 2012-31 MAY 2016 5a. CONTRACT NUMBER 5b. GRANT NUMBER GRANT10931149 5c. PROGRAM ELEMENT NUMBER 1 6. AUTHOR(S) PI: David Sulzer; Co-PI: James Goldman 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER E-Mail: ds43@cumc.columbia.edu; jeg5@cumc.columbia.edu 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Columbia University 630 West 168th Street, Box 49 New York, New York 10032-3702 grants-office@columbia.edu Ph: (212) 305-4191 Fax: (212) 305-3697 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The original goals were to explore potential mechanisms underlying epileptogenesis in Tuberous Sclerosis Complex (TSC) disease, with a focus on altered astrocyte-neuronal interactions caused by astrocyte-specific TSC deficiency. Astrocytes may contribute to abnormal neuronal excitability through mechanisms including glutamate uptake, potassium buffering and other means that alter expression and function of synaptic receptors for glutamate, or by altering the number of synapses. We chose to use a mouse GFAP (mgfap) promoter sequence directing expression of a Cre-recombinase in most astrocytes and a subpopulation of the adult stem cells in the subventricular zone. We unexpectedly found, however, that there are indeed recombinant neurons that are derived from mgfapcre expressing progenitors and are deficient for TSC1. We have compared directly and in the same brain region the effect of neuronal-intrinsic mtor activation on the morphology and physiological functions of wildtype and recombinant neurons, as well as the effects of Tsc1-deficient astrocytes on neuronal morphology and neuronal activity associated with seizures. 15. SUBJECT TERMS Tuberous Sclerosis; Epilepsy; Astrocytes; Neurons; Astrocyte-Neuron Interactions 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT Unclassified b. ABSTRACT Unclassified c. THIS PAGE Unclassified Unclassified 18. NUMBER OF PAGES 11 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code) Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18

2 Table of Contents Page 1. Introduction. 3 2. Keywords. 3 3. Accomplishments..... 4-6 4. Impact... 7 5. Changes/Problems.... 7 6. Products.... 7 7. Participants & Other Collaborating Organizations 7 8. Special Reporting Requirements 7 9. Appendices 7

3 2016 Progress report GRANT10931149 PI: David Sulzer; Co-PI: James Goldman Altered Astrocyte-Neuron Interactions and Epileptogenesis in Tuberous Sclerosis Complex Disorder Introduction This is our 2011 TSCRP Idea Development Award (07/12-6/15) final report. The original goals were to explore potential mechanisms underlying epileptogenesis in Tuberous Sclerosis Complex (TSC) disease, with a focus on altered astrocyte-neuronal interactions caused by astrocyte specific TSC deficiency. We had hypothesized that abnormal cells in non-tuber cortex might form an abnormally excitable network that underlies seizure generation in TSC. Epileptogenesis in non-tuber neural tissue in TS may thus arise by an imbalance of decreased inhibitory and increased excitatory synaptic transmission. Astrocytes may contribute to abnormal neuronal excitability through mechanisms including glutamate uptake, potassium buffering and other means that alter expression and function of synaptic receptors for glutamate, or by altering the number of synapses. To address a specific role for astrocytes in regulating synaptic function during development, we chose to use a mouse GFAP (mgfap) promoter sequence directing expression of a Cre-recombinase in most astrocytes and a subpopulation of the adult stem cells in the subventricular zone. Previous studies have reported that there is no targeting of postnatal or adult neural stem cells or their progeny in the hippocampus or other brain regions, rendering these mice particularly useful for selective targeting of astrocytes. We unexpectedly found, however, that there are indeed recombinant neurons that are derived from mgfapcre expressing progenitors and are deficient for TSC1. This provides an important new aspect of analysis: in our novel neuroglial TSC1 deficient mouse model, we are able to compare directly and in the same brain region the effect of neuronal-intrinsic mtor activation of synaptic activities on wild-type and recombinant neurons, as well as the effects of Tsc1- deficient astrocytes on neuronal morphology and neuronal activity associated with seizures. Keywords: Tuberous Sclerosis, Epilepsy, Neurons, Astrocytes, GFAP, mouse models

4 Accomplishments: Year 1: We established the mouse GFAP-Cre mediated Tsc1 conditional knockout (TSC1 mgfapcre CKO) mouse model, and found that: a) TSC1 mgfapcre CKO mice develop spontaneous clinical seizures at the age of 2.5 months; b) TSC1 mgfapcre CKO mice show astrogliosis, activated mtor signaling, and enlarged cellular size of astrocytes and a few enlarged pyramidal neurons in layer II-III cortex and in hippocampus CA1-3 regions; c) Astrocyte glutamate transport and potassium buffering functions remained intact in TSC1 mgfapcre CKO mice at 1 month and 2 months of age, prior to the onset of clinical seizures. Astrocytes do show increased GFAP and S100b immunoreactivities at 1 month, and this increase becomes more pronounced with age. However, astrocytes do not show decreases in glutamate transporter currents, and GLT-1 and GLAST immunoreactivities until 3.5 months of the age. A slight decrease in astrocyte uptake of synaptically evoked glutamate appears at the age of after the occurrence of clinical seizures; d) TSC1 mgfapcre CKO display synaptic damage induced by spontaneous seizures at the age of 3months; e) Increased spine density on pyramidal neuron dendrites at the age of one month, prior to the onset of spontaneous seizures (Figure 1). A Figure 1. Increased synaptic density in TSC1CKO mice prior to the clinical seizures. (A) dendritic segments from postnatal day 30 control (left) and TSC1CKO (right) CA1 pyramidal neurons; (B) immunolabel of presynaptic marker Vglut1 and postsynaptic marker PSD95 in hippocampal stratum radiatum. Compared to control mice, TSC1CKO mice showed increased spine density and synaptic markers. B These data suggest that the astrocyte pathology evolves slowly in our mouse model. It is possible that the major changes in astrocytes do not manifest until during or after the onset of seizures, suggesting that the seizures produce the major pathology in astrocytes. Nevertheless, the consequent astrocyte pathology may itself contribute to the ongoing seizure activity.

Year 2: We recorded miniature EPSCs, evoked EPSCs and paired pulse facilitation in wt and TSC1CKO mice at CA3- CA1 synapses at the age of 1 month and 3.5 months. We found in the mutants: 1) an increased frequency and amplitude of mepscs / evoked EPSCs in CA1 pyramidal neurons, indicative of increased neuronal excitability (Figure 2); 2) decreased paired pulse facilitation (PPF) in CA1 pyramidal neurons, suggesting an enhanced probability of presynaptic neurotransmitter release (Figure 2); 3) by recording high frequency stimulation evoked EPSCs, we found increased amplitude and increased decay time: this value indicates the amount of glutamate released at the synapse, the amount of extracellular glutamate molecules available for transport, and the expression of transporter proteins. A B C 5 Figure 2. Neuronal activities in TSC1 mgfapcre CKO mice. (A) Representative traces showing miniature EPSC (mepsc) activity in control and Tsc1 CKO CA1 pyramidal neurons. These preliminary results imply changes in both frequency and amplitude of miniature EPSCs in CA1 pyramidal neurons of Tsc1 CKO mice, indicative of increased excitatory synaptic transmission; (B) Representative evoked EPSC traces in CA1 pyramidal neurons from control and Tsc1 CKO mice. The increase in the EPSC amplitude suggests that Tsc1 CKO astrocytes effect on neuronal activity via a postsynaptic mechanism; (C) Paired-pulse facilitation is reduced in the CA1 pyramidal neurons in Tsc1 CKO mice, indicative of a possible change in presynaptic release probability. Together, these independent findings confirm an increase in excitatory neural transmission in our TSC1 mgfapcre CKO mice during epileptogenesis. As we failed to detect significant changes in astrocyte glutamate uptake and potassium buffering, we further examined why pyramidal neurons show enhanced excitability. As mentioned above, we observed some dysplastic neurons with enlarged soma size and high levels of phospho-s6 in layer II-III cortex and in hippocampal pyramidal layers in the TSC1 mgfapcre CKO mice. To determine the origin of these dysplastic neurons and whether behavioral seizures are due to enhanced intrinsic excitability of these neurons, we developed a novel TSC1 mgfapcre CKO mouse model expressing a LoxP-stop- LoxP-dtomato cassette (TSC1 mgfapcre CKO:Ai9-dtomato+), in which the expression of Cre recombinase can drive the expression of dtomato in Cre expression brain cells. Our findings in this new mouse model include: a) A pool of dtomato-positive,tsc1-deficient recombinant pyramidal neurons in the superficial isocortical layers (II-III) and in the hippocampal pyramidal layer, indicating a radial glial origin of these late-born excitatory neurons. b) In TSC1 mgfapcre CKO mice, most of these recombinant neurons expressed high levels of ps6 at the age of 1 month, suggesting overactive mtor in response to the loss of TSC1 alleles. With age, some recombinant neurons maintained high levels of ps6 and displayed increased soma volume and increased dendritic trees. Interestingly, some recombinant neurons did not increase in size, but remained a normal size, compared to pyramidal neurons in the same layers that did not show Crewrecombination. This normal size suggests that these neurons possess a negative feedback mechanism that in part counteracts the effect of the TSC1 deletion. c) We have compared dendritic spine density of mgfapcre recombinant (dtomato+) and nonrecombinant (dtomato-) neurons in both Tsc1wt:Ai9-dtomato+ an d TSC1mGFAPCre CKO; Ai9-dtomato+ mice. Using DiOlistic labeling technique, we found that TSC1-deficient recombinant neurons exhibit more dendritic spines than wild type, non-recombinant neurons. The latter show a similar spine density to that of pyramidal neurons in a TSC1 wild type, mgfapcre-expressing Ai9 dtomato mice. These data

6 suggest that the increased excitability in TSC1 mgfapcre CKO mice might be due to Cre-expressing recombinant excitatory neurons and that the Cre and dtomato expression do not alter spine density. d) Tsc1 deletion prior to the biogenesis of neurites would impact the complexity of the dendritic tree. We crossed the Tsc1flox/flox mice to the Ai9 Cre reporter mice to obtain Tsc1flox/flox;Ai9+ and Tsc1+/+;Ai9+ pups. We isolated neurons to establish in primary cultures, and transfected neurons from Tsc1flox/flox:Ai9+ or Tsc1+/+;Ai9+ mice pups with Cre expressing plasmids before plating into cultures. Cre recombinase will drive dtomato expression, which allows the imaging of dendritic spines in neurons in vitro, and removes the Tsc1 gene from Tsc1flox/flox neurons. Compared to Tsc1+/+; Creexpressing control neurons, Tsc1flox/flox;Cre-expressing Tsc1 CKO neurons exhibit significantly more primary and secondary dendrites, causing them to appear dysplastic. The increased dendritic complexity in TSC1 CKO recombinant, dysplastic neurons was confirmed in brain slices using luciferase yellow injection. Compared to non-recombinant neurons, dysplastic neurons showed a larger soma size and an increased basal dendritic tree complexity (Figure 3). Figure 3. Increased dendritic tree complexity in cultured Tsc1CKO neurons. Year 3: We continued to characterize the physiological properties of 1) dtomato+ recombinant Tsc1KO neurons in TSC1 mgfapcre CKO: Ai9-dtomato+ mice, 2) dtomato- non-recombinant neurons in the TSC1 mgfapcre CKO: Ai9-dtomato+ mice, 3) dtomato+ pyramidal neurons in mgfapcre+:ai9-dtomato+ Tsc1 wild type control mice, and 4) dtomato- pyramidal neurons in mgfapcre+:ai9-dtomato+ control mice. All mice were examined at the age of 3.5months. a) Intrinsic membrane properties. Compared to dtomato- neurons in TSC1 mgfapcre CKO: Ai9- dtomato+ mice, dtomato+ and dtomato- pyramidal neurons in mgfapcre+:ai9-dtomato+ mice, TSC1KO dtomato+ pyramidal neurons in TSC1 mgfapcre CKO: Ai9-dtomato+ mice exhibited increased membrane capacitance and decreased Membrane input resistance; b) Spontaneous miniature excitatory postsynaptic currents (mepscs). mepscs were recorded in the presence of 1mM Tetrodotoxin (TTX) and 50mM picrotoxin. We found that the dtomato+ recombinant TSC1 knockout neurons show increased frequency of miniature EPSCs, increased amplitude of mepscs and a prolonged decay, compared to wild type, non-recombinant neurons in the TSC1 mgfapcre CKO mice and to dtomato+ and dtomato- pyramidal neurons in TSC1 wild type, mgfapcre expressing Ai9 dtomato mice. c) Action potential (AP) and afterdepolarization (ADP). Action potentials were evoked in neurons with brief (2 and 4 msec) depolarizing current pulses through the recording electrode. AP firing patterns were examined by injecting neurons with long depolarizing current (300 msec) (up to 400pA). TSC1KO dtomato+ pyramidal neurons in TSC1 mgfapcre CKO: Ai9-dtomato+ mice exhibited lower action potential threshold, elevated or prolonged ADP, or fast AP firing pattern than all of the other three types of neurons (Figure 5). d) Presence of spontaneous paroxysmal depolarization shift (PDS). PDS is a sudden, large depolarization of membrane potential, which lasts more than 100 msec and usually triggers spike firing (Johnston 1984), often observed with intracellular recording in focal or generalized convulsive epilepsy, characterized by a giant excitatory postsynaptic potential with a burst of action potentials riding on it and followed by a long period of hyperpolarization. PDS can be a network-driven synchronizing event and is an intracellular correlate for the interictal EEG spikes. We found that PDS can only be induced in dtomato+ neurons in TSC1 mgfapcre CKO mice, but not in dtomato- neurons in TSC1 mgfapcre CKO mice and both dtomato+ and dtomato- neurons from mgfapcre+;ai9-dtomato+ control mice.

7 e) Seizure-like activity induced by weak chemical/electrical stimulation. Local pressure ejection of a weak NMDA receptor agonist, 1mM aspartic acid (4 sec, 10Kpa) induces transient NMDA receptordependent depolarization (plateau potential) and spike firing (Suzuki, 2008) in both dtomato+ and dtomato- neurons in mgfapcre+:ai9-dtomato+ control mouse cortex, and in dtomato- neurons in TSC1 mgfapcre CKO: Ai9-dtomato+ mouse cortex. In contrast, dtomato+ dysplastic neurons in TSC1 mgfapcre CKO: Ai9-dtomato+ mouse brain showed prolonged slow-depolarization after initial burst-firing induced by NMDA R agonist, followed by a sustained afterdischarge, indicative of longlasting seizure-like activity (Figure 4). The aspartate-driven depolarization was blocked by an NMDA antagonist (Figure 6). A Figure 4. Prolonged discharge observed in the cortical pyramidal neurons in Tsc1mGFAPCreCKO mice. (A) Represented luciferase yellow injected normal size wild type (upper) and dysplastic Tsc1GFAPCreCKO (lower) neurons pyramidal neurons in cortical layers II-II. (B) Induction of electrographic seizures in dtomato negative (Upper) and positive (Lower) neurons in Tsc1GFAPCreCKO mice. B

8 A B Figure 5. Cortical pyramidal neurons from TSC1 CamKII-cre CKO mouse show intrinsic membrane hyperexcitability. A. An enhanced afterdepolarization (ADP) after a single action potential (AP) induced with a short depolarizing current pulse (2 ms, 2 na) was observed only in pyramidal neurons from TSC1 CamKII-cre CKO mouse, but not in pyramidal neuron from TSC fl/fl mouse. B. Example of voltage response to current injection through patch electrode (-200pA to 400 pa, 300ms). The number of action potential was greater in TSC1 CamKII-cre CKO pyramidal neurons than in control neurons in response to 200, 300 and 400pA current injection. A Figure 6. The NMDA receptor agonist aspartic acid (1 mm) induces a prolonged membrane depolarization in cortical pyramidal neuron from Tsc1 CamkII-Cre CKO mouse. A. Focally applying aspartic acid evoked action potential firing and membrane depolarization in cortical pyramidal neurons (PYN). TTX (1uM) blocked the induced action potential firing, but not membrane depolarization. The NMDA receptor antagonist (MK-801) almost completely blocked membrane depolarization. Year 4 We have asked for and received a one-year no cost extension to complete data analysis and to prepare the manuscript. During this year, we have continued our electrophysiological analysis of excitability of dtomato+ TSC1KO neurons in the TSC1 mgfapcre CKO: Ai9-dtomato+ mice at different ages (1month, 2 months and 3.5months). We have increased the sample size for each measure to ensure that we have sufficient power to detect significant differences between groups. At all ages, the Tsc1KO dtomato+ neurons in the TSC1KO mice exhibit increased frequency of miniature EPSCs, increased amplitude, prolonged decay, and lower threshold for action potentials, compared to dtomato- neurons in the TSC1KO mice, and to dtomato+ and dtomato- neurons in mgfapcre+:ai9-dtomato+ control mice. However, PDS and seizure like activities induced by weak chemical or electrical stimulation can only be evoked in recombinant TSC1KO neurons in TSC1 mgfapcre CKO: Ai9-dtomato+ mice at the age of 3.5months, when these neurons become dysplastic. We have characterized the temporal expression pattern of mouse GFAPcre during embryonic ages. Using Ai9 dtomato+ Cre reporter mice, we have examined the mouse GFAPCre mediated recombination at embryonic day 12 (E12), 15(E15), 18(E18), 19(E19) and 21 (E21). The Cre mediated dtomato expression begins on E18 in a small set of neural progenitors. Ongoing studies are to examine whether there is an age-dependent increase in mgfapcre mediated neuronal recombination events. We measured pre- and post-synaptic protein levels during development, at the ages of 1month, 2months and 3.5months. At the age of 1 month, prior to the onset of behavioral seizures, we found an increase in protein levels of pre- and postsynaptic proteins, including synapsin I, NR2B, GluR1 and GluR2, in the TSC1 mgfapcre CKO mice. These data are consistent with our findings of increased dendritic spine synapses in

9 Tsc1KO neurons in the TSC1 mgfapcre CKO mice. Our ongoing experiments are to determine the synaptic components specifically in the mgfapcre expressing neurons in control and TSC1 mgfapcre CKO mice. In summary, we have established several TSC mouse models based on the mgfap-cre TSC1 CKO mouse. We have made a number of fundamental anatomic, electrophysiological and molecular observations. These include 1. the development of dysplastic, cytomegalic neurons, which display a number of the changes of hyperexcitable neurons in epilepsy; 2. increases in dendritic spine density produced by TSC1 CKO; 3. changes in astrocyte size, GFAP levels, and glutamate transporter currents, but these changes occur during or after the onset of seizures; 4. Normal, non-recombinant pyramidal neurons are surrounded by recombinant astrocytes, suggesting that TSC1-deficient astrocytes are not in themselves able to convert a pyramidal neuron to a dysplastic, hyperexcitable neuron. These novel observations are helping us to understand the pathology and clinical phenotype of TSC. We are in the process of writing up a manuscript to report our findings. We have most of it written, but still require a few more electrophysiological recordings and protein assays to have enough observations for statistical significance testing.

10 Impact: As noted above, our novel observations stand to add to our knowledge of the mechanisms of seizures and anatomic pathologies in TSC significantly. Specifically, our new neuronal-glial mouse model of TSC1 deficiency has allowed us to compare directly and in the same brain region the effect of neuronal-intrinsic mtor activation on synaptic activities and morphology of TSC1 deficient neurons with those that contain normal levels of TSC1. This has allowed us to begin to define in detail the molecular changes that neurons udergo as a result of TSC1 deletion. We have also been able to distinguish the effects of Tsc1-deficient astrocytes on neuronal morphology and neuronal activity associated with seizures. We will be able to learn in detail how the pathology of TSC is established and hopefully, based on molecular evaluations, suggest new strategies for therapies. Changes/Problems: None Products: None Participants & Other Collaborating Organizations: None Special Reporting Requirements: None Appendices: None